Skip to main content
. Author manuscript; available in PMC: 2009 Oct 2.
Published in final edited form as: Eur J Immunol. 2008 Dec;38(12):3450–3458. doi: 10.1002/eji.200838640

Fig. 4. Reduced incidence of arthritis in APRIL−/− mice.

Fig. 4

A. Incidence: APRIL−/−: 56.3 % (n=16), APRIL+/−: 90.0% (n=20), APRIL+/+: 92.3% (n=13), Adjuvant controls: 0% (n=9). p=0.044 (−/− vs +/+), p=0.049 (+/− vs −/−) and p=1.000 (+/− vs +/+), Fisher’s exact test; B. Percentage of newly arthritic mice during different onset days. C. Clinical scroes (disease severity) of affected mice. APRIL−/−: n=10, APRIL+/−: n=18, and APRIL+/+: n=12 (C); Data from 4 independent experiments were combined (A–C). D, E. Normal and CIA paws of APRIL+/+ mice. D. Normal paw of an adjuvant control mouse. E. CIA paw with erythema and swelling of a CII injected mouse. F, G. Histological assessment of paw joints of APRIL+/+ mice. F shows an adjuvant control joint with even and clear joint space and smooth articular cartilage. G shows a CIA joint with infiltration of inflammatory cells, cartilage destruction and bone erosion. H&E, Original magnification: 20x.